Welcome Guest to Happi

Subscribe Free: Magazine | eNewsletter

current issue December 2014
 •  Coast Southwest Promotes Hoff  •  Tweezerman Names New CEO  •  Kiss My Face Brings Back Bar Soaps  •  New Leadership at Wacker  •  Lauder Goes Glam
Print

32. Chattem



Published July 11, 2011
Related Searches: hair sales president men
32. Chattem

Chattanooga, TN

800.366.6077

www.chattem.com

Sales: $336 million


Sales:

$336 million (estimated) for personal care products. Corporate sales: $40.3 billion.


Key Personnel:

Christopher A. Viehbacher, chief executive officer of Sanofi-Aventis; Greg Irace, president and CEO, Sanofi-Aventis US; and Zan Guerry; chief executive officer of Chattem Inc.; Robert E. Bosworth, president, chief operating officer, Chattem Inc.


Major Products:

Medicated skin care—Gold Bond, Cortizone 10, Aspercreme, Arthritis Hot, Sportscreme, Capzasin; Skin care—Balmex; Oral care—Act mouthwash; Hair care—Selsun Blue, Sun-In, Ultra Swim; Sun care—BullFrog, UltraSwim.


Comments:

Sanofi Aventis has completed the acquisition of Chattem, Inc., pulling its well-known personal care brands like Gold Bond, Balmex and BullFrog—as well as Allegra (the main thrust behind the French drug company’s purchase of Chattem in the first place)—into its consumer healthcare business. In 2010, that business sector tallied sales of $2.2 billion. Since the acquisition date, Chattem generated net sales of €328 million and business net income of €110 million, according to the company’s annual report of the year ended Dec. 31, 2010.


Late last year, Chattem opened a new manufacturing facility on Broad Street in Chattanooga, which Chattem’s CEO Zan Guerry, said “was completed on time and within budget and created numerous new jobs” for the local community. The facility reportedly manufactures Chattem’s Act mouthwash brand. Still, Chattem’s focus for 2011 seems to be on Allegra, as this past spring the company completed the biggest launch in its history—the OTC rollout ofthe well-known allergy medication.



blog comments powered by Disqus